|

MethylGene Inc., a biopharmaceutical company seeking treatment for cancer and infectious diseases, completed a bought deal financing with an underwriting syndicate led by Canaccord Capital Corporation and including Blackmont Capital Inc., Raymond James Ltd. and Clarus Securities Inc.  Pursuant to the deal, MethylGene Inc. agreed to sell 5,500,000 common shares at a price of $3.65 per share, resulting in gross proceeds to MethylGene of approximately CDN$20 million.  Davies advised MethylGene on the deal.

|

2007